
New paper sheds light on experience of Black prisoners in infamous Stateville prison malaria experiments
Much has been said and written over the years about controversial malaria research conducted on inmates at Illinois' Stateville Penitentiary starting in the 1940s.
But at least one part of that story has been largely ignored until now: the role of Black prisoners in that research, which helped lead to the modern practice of using genetic testing to understand how individual patients will react to certain medications, according to the authors of a newly published paper out of the University of Utah.
'We want to highlight the stories of Black prisoners that participated in this prison research in the 1950s onward and give them their due,' said Hannah Allen, a medical ethicist and assistant professor of philosophy at the University of Texas Rio Grande Valley, and first author of the paper, which was published as an opinion piece Wednesday in the Journal of the American Medical Association.
'They haven't been properly acknowledged in the past, and their participation in these studies was really foundational in launching the field of pharmacogenetics and, later on, precision medicine,' said Allen, who recently completed her doctorate at the University of Utah.
Starting in the 1940s, researchers infected inmates at the Joliet-area prison with malaria to test the effectiveness of drugs to treat the illness as part of a U.S. military-funded effort to protect American troops overseas, according to the paper. A University of Chicago doctor was the principal investigator. The inmates consented to being part of the studies and were paid for their participation.
At first, the research was greeted with enthusiasm. In 1945, Life magazine ran a spread about it, featuring a photo of a Stateville inmate with cups containing malaria-carrying mosquitoes pressed against his bare chest. The first line of the story reads, 'In three U.S. penitentiaries men who have been imprisoned as enemies of society are now helping science fight another enemy of society.'
But as the years passed, attitudes began to shift. Questions arose about whether inmates could truly, freely consent to participate in medical experiments or whether they felt coerced into them because of their often dire circumstances.
At the Nuremberg trials, defense attorneys for Nazi doctors introduced text and images from the Life article about Stateville prison, though an Illinois physician argued at the trials that the prisoners in Stateville consented to being part of medical research whereas Nazi prisoners did not, according to the JAMA paper.
In the mid-1970s, news broke about a study at Tuskegee, in which Black men with syphilis went untreated for years — news that raised awareness of ethical problems in medical research.
News outlets also began publishing more stories about prison research, according to the JAMA article. The Chicago Tribune published an article in 1973, in which an inmate participating in the Stateville malaria research said: 'I've been coerced into the project — for the money. Being here has nothing to do with 'doing good for mankind' … I didn't want to keep taking money from my family.'
The experiments at Stateville came to a halt in the 1970s. A number of protections and regulations are now in place when it comes to research involving prisoners.
Since the 1970s, the Stateville research has often been discussed and analyzed but little attention has been paid to its Black participants, said James Tabery, a medical ethicist and philosophy professor at the University of Utah who led the new research, which was funded by the federal National Institutes of Health.
For a time, Black prisoners were excluded from the studies because of a myth that Black people were immune to malaria, Tabery said. Later on, once scientists had pinpointed the drug primaquine as an effective medication for malaria, they turned their attention to the question of why 5% to 10% of Black men experienced a violent reaction to the drug, according to the paper.
Ultimately, the scientists were successful, finding that the adverse reaction was related to a specific genetic deficiency.
'There are people all over Chicago today that are getting tested, that clinicians are recommending they get a genetic test before they get prescribed a drug because they want to make sure that their patient isn't going to have an adverse reaction to the drug,' Tabery said. 'It's really sort of powerful and interesting that you can trace that approach to doing good clinical medicine right back to this particular moment and place and population.'
But Tabery and Allen also found that the Black prisoners were not treated the same as the white prisoners who participated in research at Stateville.
For one, they weren't paid as much as the white prisoners, the rationale being that the white prisoners were infected with malaria, whereas the Black prisoners were given the drug but not infected with the disease — though some of the Black prisoners got very ill after taking the medication, according to the paper.
Also, researchers didn't protect the Black participants' privacy as well as they did for other participants. They published certain identifying information about the Black participants, such as initials, ages, heights and weights, whereas participants in the previous research were represented with case numbers, according to the paper.
Researchers also recruited the Black prisoners' family members for the study, which they didn't do with earlier participants, according to the paper.
'You see them just doing things with the Black prisoners that they're not doing with the white prisoners,' Tabery said.
Also, though scientists made an important discovery through the research on Black prisoners, the episode also highlights the difficulty that can occur in translating discoveries into real life help for patients. Though the World Health Organization now recommends genetic testing to protect people who are sensitive to antimalarials, many of the people who would benefit most from such testing still don't receive it because of financial barriers, supply chain issues and a lack of training, according to the paper.
'What we found is when you sort of shift to what was happening to the Black prisoners, these other lessons you hadn't thought of as being derivable from Stateville suddenly do become apparent,' Tabery said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
What is ‘tech neck' and how can you fix it?
With nearly 86 percent of full-time American workers spending long, unhealthy hours sitting at their desks, leaning over computers, or staring down at their phones, many have found themselves suffering from 'tech neck.' The condition, sometimes also referred to as 'text neck," is used to describe pain and discomfort in the neck that can happen when someone bends their head down. The problem is pressure, with experts saying that holding your head at a 45-degree angle can feel like 50 pounds of weight. "That's like having an 8-pound bowling ball as your head. Then you have 72 pounds at your elbow and 96 pounds on your shoulder," Brian Langenhorst, industrial and ergonomics specialist at Wisconsin's La Crosse Mayo Clinic Health System, said. "I probably see tech neck on a weekly basis at businesses, schools and industry." There has been an increase in cases in recent years, but there are ways to prevent the condition. Here's how to fix it. Stretches should be done frequently for the best benefits, according to sports medicine Dr. Jeffrey Peng. "Five minutes is really all you need to stretch out the neck," he said. "But the key is to do these stretches frequently — ideally, three times per day. That way, you are slowly increasing mobility and range of motion of the neck muscles that often get tighter and tighter throughout the day.' He recommends touching your ear to your shoulder to stretch the upper trapezius, a large shoulder muscle. For further pressure, put gentle pressure on your head using your hand. Hold it for 30 seconds. You can also stretch the levator scapula: a neck muscle that runs along the upper back on neck on either side of the spine. With the head turned diagonally, pull down on it with one hand and guide the other hand to rest on the base of the neck. To target the anterior scalene — which helps to flex the neck and elevate the first rib — pull the ear toward the shoulder, look up, and lean back. Adjust your monitor to the right level, with eye height about a half inch to one and a half inches higher than the top characters on your screen. Sit with your head, hips, and spine stacked, and keep your wrists straight and elbows bent at a 90-degree angle. Your feet should be flat on the floor and your knees should be aligned with your hips. When using a phone, place pillows on your lap to support your forearms and try to hold the phone or tablet in an upright and angled position. By looking straight ahead, your muscles get a chance to relax, preventing uneven pressure. "It's not great, but it's better than not being supported," said Langenhorst. Take frequent screen breaks and get up and move! That will get blood circulating and it will get your neck in a different position. Or, even just stand. 'Humans are upright creatures, and our bodies aren't designed to look down for long periods of time, which puts extra pressure on the cervical spine,' Dr. Kavita Trivedi, an associate professor at UT Southwestern Medical Center, said.
Yahoo
an hour ago
- Yahoo
Bernie Sanders, Angus King Propose Drug Advertising Ban in Consumer Marketing
Sens. Bernie Sanders and Angus King have introduced new legislation that would ban prescription drug advertising on television, radio, print, digital platforms and social media. The bill, known as the End Prescription Drug Ads Now Act, would apply to all drugs and biologics, including those currently on the market. 'With the exception of New Zealand, the United States is the only country in the world where it is legal for pharmaceutical companies to advertise their drugs on television. It is time for us to end that international embarrassment,' Sanders said in a statement. 'The American people don't want to see misleading and deceptive prescription drug ads on television. They want us to take on the greed of the pharmaceutical industry and ban these bogus ads.' The lawmakers note that the 10 largest drug companies made more than 100 billion in profits last year, with the pharmaceutical industry spending over $5 billion on television ads. They added that prescription drug commercials account for more than 30% of commercial time on major networks' evening news programs and that Big Pharma spent over $725 million advertising just 10 drugs in the first three months of 2025. Additionally, the pair noted that the prices for drugs in the U.S. are among the highest in the world, with one in four Americans not able to afford the costs of the medicine their doctors prescribe. For example, Novo Nordisk charges nearly $1,000 a month for Ozempic in the United States, compared to $59 in Germany, $71 in France, $122 in Denmark, and $155 in Canada, and $1,349 a month for Wegovy, compared to $92 in the United Kingdom, $137 in Germany, $186 in Denmark and $265 in Canada. 'The widespread use of direct-to-consumer advertising by pharmaceutical companies drives up costs and doesn't necessarily make patients healthier,' King added. 'The End Prescription Drug Ads Now Act would prohibit direct-to-consumer advertising of pharmaceutical drugs to protect people. This bill is a great step to ensure that patients are getting the best information possible and from the right source: their providers and not biased advertisements.' The introduction of the End Prescription Drug Ads Now Act follows repeated calls from Health and Human Services Secretary Robert F. Kennedy Jr. calling for a ban on prescription drug advertising. The Campaign for Sustainable Rx Pricing estimates that prohibiting pharmaceutical advertising could increase federal tax revenues by $1.5 to $1.7 billion annually from 10 of the largest pharmaceutical companies operating in the U.S. In addition to Sanders and King, cosponsors of the legislation include Democratic Sens. Chris Murphy, Peter Welch, Jeff Merkley and Dick Durbin. More to come… The post Bernie Sanders, Angus King Propose Drug Advertising Ban in Consumer Marketing appeared first on TheWrap.


Newsweek
an hour ago
- Newsweek
Bernie Sanders Introduces Bill Backing RFK Jr., Elon Musk Priority
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Senator Bernie Sanders is leading a new bill to address a key priority of Robert F. Kennedy Jr., who serves as President Donald Trump's Health and Human Services Secretary. Why It Matters Sanders, a Vermont independent, alongside Senator Angus King, a Maine independent, introduced the "End Prescription Drug Ads Now Act," which, if passed, would ban prescription drug advertising on TV, radio, print and digital platforms as well as social media. Critics say these ads contribute to the high price of healthcare while doing little to improve care in the United States, though proponents say the advertisements can improve patients' knowledge of healthcare. Most wealthy countries, with the U.S. and New Zealand being two notable exceptions, ban pharmaceutical drug advertisements. The bill also represents an issue where Sanders, viewed as perhaps the most progressive senator, has found common ground with Kennedy inside the Trump administration, though the secretary has not commented on this bill specifically. What to Know Sanders and King announced the legislation on Thursday, highlighting that the pharmaceutical industry spent more than $5 billion on TV ads in 2024 and that many of these drugs cost more in the U.S. than in other countries that do not allow drug companies to run ads on TV. "The American people are sick and tired of greedy pharmaceutical companies spending billions of dollars on absurd TV commercials pushing their outrageously expensive prescription drugs," Sanders said, describing the fact that the U.S. stands mostly alone in allowing pharmaceutical ads as an "international embarrassment." vSenator Bernie Sanders, a Vermont independent, questions U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. during a committee hearing on May 14, 2025 in Washington, D.C. vSenator Bernie Sanders, a Vermont independent, questions U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. during a committee hearing on May 14, 2025 in Washington, director of communications Anna Bahr confirmed to Newsweek his office has reached out to Republicans to join the bill. Bahr pointed to lobbying from the pharmaceutical and health insurance industries as to why the U.S. has not joined other countries in bannign the ads. "Over the past 25 years, the drug companies have spent $8.5 billion on lobbying. Today, they have some 1,800 well-paid lobbyists in Washington, D.C. – including former leaders of the Republican and Democratic parties," she said in a statement to Newsweek. "Unbelievably, that is more than three lobbyists for every member of Congress. During that same period, they have provided over $700 million in campaign contributions. And they are equal opportunity contributors. They contribute heavily to both Republican and Democratic candidates." Secretary Kennedy—as well as Elon Musk, who previously served in Trump's administration—have expressed support for ending pharmaceutical advertising. "Let's get President Trump back in the White House and me to DC so we can ban pharmaceutical advertising," Kennedy wrote in a post to X (formerly Twitter) on November 3, 2024. During his own presidential campaign, Kennedy said he would have issued an executive order ending the advertisements on his first day in office. Newsweek reached out to DHS for comment via the department's press contact form. Caleb Alexander, professor of epidemiology at the Johns Hopkins University Bloomberg School of Public Health, told Newsweek that while a potential ban's impact on drug prices remains uunclear, there would be benefits to ending these advertisements. Pharmaceutical advertisements can drive up "inappropriate demand" for prescription drugs in settings where they may not be needed, he said. "In terms of the potential benefits of banning [direct-to-consumer advertisements], the most immediate and likely is that it would temper demand for products in settings where they may not be needed," Alexander said. The U.S. has "evolved to believe" the benefits of the ads, such as empowering patients to identify health concerns, outweigh the risks, though much of the research on the topic indicates that the benefits may not be worth the drawbacks, he said. What People Are Saying Alexander told Newsweek: "Direct to consumer advertising has been a lightning rod for controversy, and it remains a curious and unique feature of the U.S. marketplace. While a ban on direct advertising may be welcomed by many, it's not going to fundamentally transform the marketplace for prescription drugs in the United States, simply because DTCA is highly concentrated among a small number of products. It may be a reasonable political and public health target, but I think that if you just look at the way the dollars flow, there's vastly more money spent on marketing drugs to prescribers." Senator Angus King wrote in a statement: "The widespread use of direct-to-consumer advertising by pharmaceutical companies drives up costs and doesn't necessarily make patients healthier. The End Prescription Drug Ads Now Act would prohibit direct-to-consumer advertising of pharmaceutical drugs to protect people. This bill is a great step to ensure that patients are getting the best information possible and from the right source: their providers and not biased advertisements." Elon Musk wrote to X in November 2024: "No advertising for pharma." What Happens Next It's unclear whether a majority of senators are also in support of the bill. So far, Democratic Senators Chris Murphy of Connecticut, Peter Welch of Vermont, Jeff Merkley of Oregon and Dick Durbin of Illinois have co-sponsored the bill, according to Sanders' office.